Verapamil - Calosyn Pharma

Drug Profile

Verapamil - Calosyn Pharma

Latest Information Update: 18 Apr 2016

Price : $50

At a glance

  • Originator Calosyn Pharma
  • Class Antihypertensives; Antimigraines; Class IV antiarrhythmics; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Musculoskeletal pain

Most Recent Events

  • 18 Apr 2016 No recent reports on development identified - Phase-I/II for Musculoskeletal pain in USA (Intra-articular)
  • 06 Feb 2014 Calosyn Pharma terminates phase I/II trial in Musculoskeletal pain in USA (NCT01645709)
  • 21 Mar 2013 Chemical structure added (USAN); str saved as MOL and PNG files
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top